In this part two, we discuss what is required for success in market access efforts as well as how to avoid common pitfalls.

In this article, we explore an initial impact analysis of Trump's 'Most Favored Nations' executive order which will put enormous pressure on the industry.

Learn more about the crossroads we are at to lower U.S. healthcare costs and saving Medicare and Medicaid for future generations.

To execute IEPs that allow companies to realize the full value of their products, several historical flaws must be addressed. In part one, we explore four of those critical themes.

This primer examines how pharmaceutical investment decisions must consider market access factors to be effective.